We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HEN3:XETRHenkel AG & Co. KGaA Pref Analysis

Data as of 2026-03-13 - not real-time

€70.08

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Henkel (HEN3) is trading at €70.08, comfortably above its 30‑day support of €68.94 but still below the 20‑day SMA of €78.70 and the 50‑day SMA of €75.97, indicating a short‑term price lag. The RSI of 26.2 places the stock in oversold territory, while the MACD remains bearish, suggesting a potential near‑term rebound amid a broader bullish trend direction. Valuation metrics show a forward P/E of 11.9 and a trailing P/E of 14.0, with the DCF‑derived fair value at €46.79, implying the market is pricing a modest premium but still within a reasonable range given the target median price of €76.5. The dividend yield of 2.91% and a payout ratio of 40.8% are supported by strong operating cash flow of €2.54 bn and a free cash flow conversion of roughly €1.47 bn, underscoring dividend sustainability.
The company’s defensive consumer‑goods positioning, low beta (≈0.12) and modest 30‑day volatility of 27.6% mitigate market risk, though regulatory exposure in chemicals and a global geographic footprint introduce medium‑level regulatory and geographic risks. With a solid gross margin of ~51% and operating margin near 12%, earnings remain resilient despite a 6.3% revenue contraction, and the balance sheet shows manageable debt levels (debt‑to‑equity ~18%). Overall, the stock presents a fair‑valued, dividend‑rich opportunity with upside potential of roughly 12% while maintaining a defensive risk profile.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • RSI in oversold region suggesting price rebound
  • Price just above key support level with increasing volume
  • Defensive sector and low beta reducing short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Stable cash generation supporting dividend payout
  • Forward P/E below 12 indicating reasonable valuation
  • Broad geographic diversification balancing growth and risk

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Consistent dividend yield with sustainable payout ratio
  • Defensive consumer‑goods exposure in a low‑growth environment
  • Low beta and modest volatility reinforcing defensive profile

Key Metrics & Analysis

Financial Health

Revenue Growth-6.30%
Profit Margin9.93%
P/E Ratio14.0
ROE9.71%
ROA5.09%
Debt/Equity18.02
P/B Ratio1.4
Op. Cash Flow€2.5B
Free Cash Flow€1.5B

Technical Analysis

TrendBullish
RSI26.2
Support€68.94
Resistance€84.20
MA 20€78.70
MA 50€75.97
MA 200€71.50
MACDBearish
VolumeIncreasing
Fear & Greed Index73.32

Valuation

Fair Value€46.79
Target Price€78.34
Upside/Downside11.78%
GradeFair
TypeValue
Dividend Yield2.91%

Risk Assessment

Beta0.12
Volatility27.61%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.